Last reviewed · How we verify
NCT06982391: ReACT
Compassion, Social Support, Flexibility, and Resilience Program for Women Surviving Breast Cancer
NA trial testing Resilience-Focused Acceptance and Commitment Therapy (ReACT) Program in Breast Cancer Survivor in 20 participants. Enrolling by invitation.
15 January 2026
Quick facts
| Lead sponsor | Medipol University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 12 April 2025 |
| Primary completion | 15 January 2026 |
| Estimated completion | 15 April 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Resilience-Focused Acceptance and Commitment Therapy (ReACT) Program
- No intervention
Conditions studied
- Breast Cancer Survivor — all drugs for Breast Cancer Survivor →
- Mastectomy — all drugs for Mastectomy →
Sponsor
Medipol University
Who can join
Adults 18 to 65, female only, with Breast Cancer Survivor or Mastectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate the effects of an Acceptance and Commitment Therapy (ACT) based program (ReACT) to increase social support, compassion and psychological flexibility on psychological resilience in women undergoing mastectomy. The main question it aims to answer is: Does the ReACT program improve participants' resilience by increasing social support, compassion, and psychological flexibility? Researchers will compare intervention group to control group to see if ReACT program works to improve participants' resilience. Researchers will randomly divide participants into two groups: intervention group and control group. * Participants will complete some questionnaires. * Participants in the intervention group will join a 3-week ACT-based psychological flexibility program. This program consists of sessions that last 90 minutes each. The program adopts the core principles of ACT and aims to help participants develop skills in mindfulness, acceptance, value-driven living, and cognitive defusion. * Participants will complete the same questionnaires again after the program. * Participants will complete the same questionnaires again 1 month after the program ends.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06982391
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Survivor
Currently open trials in the same condition.
- NCT07015944 — Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan · NA · recruiting
- NCT07083518 — Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors · NA · active not recruiting
- NCT06938555 — The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors · NA · recruiting
- NCT06671730 — Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast · NA · recruiting
Other Medipol University trials
Trials by the same sponsor.
- NCT07277803 — Device-Based vs Manual Sensory Training in Low Back Pain · NA · not yet recruiting
- NCT07214636 — Development and Investigation of the ApneaTheraPlay · NA · not yet recruiting
- NCT07534475 — Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT · NA · not yet recruiting
- NCT07534488 — Sacral Erector Spinae Plane Block in Pilonidal Sinus Surgery · NA · not yet recruiting
- NCT07525648 — Comparison of the Effects of Sevoflurane and Desflurane on Optic Nerve Sheath Diameter During Laparoscopic Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06982391 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medipol University
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06982391.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing